OncLive TV

Dr. Turaga on Surgery Versus Immunotherapy in Melanoma

March 30th 2017

Kiran K. Turaga, MD, associate professor of surgery, vice chief, section of general surgery and surgical oncology, director of the Surgical GI Cancer Program and the Regional Therapeutics Program at The University of Chicago Medicine, discusses whether patients vie for immunotherapy versus surgery as treatment for their melanoma.

Dr. Fanale on Challenges Facing Treatments in T-Cell Lymphoma

March 30th 2017

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

Dr. Fowler on Different Responses to Therapy for Follicular Lymphoma

March 30th 2017

Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the differences in response to the same therapy for patients with follicular lymphoma.

Dr. Yarmand Discusses Targeting ATF4 in Thyroid Cancer

March 29th 2017

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses targeting ATF4 in medullary thyroid cancer.

Dr. Lorch on the Treatment of Medullary Thyroid Cancer

March 29th 2017

Jochen H. Lorch, MD, director, Thyroid Cancer Center, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the current treatment landscape of medullary thyroid cancer.

Dr. Shea on Dermatological Management in Melanoma

March 29th 2017

Christopher R. Shea, MD, the Eugene J. Van Scott Professor of Medicine, chief of the Section of Dermatology at The University of Chicago Medicine, discusses the dermatological management of melanoma.

Dr. Ramanathan on Treatment Resistance in Pancreatic Cancer

March 29th 2017

Ramesh K. Ramanathan, MD, vice chair of research in the Department of Hematology/Oncology at Mayo Clinic, discusses why pancreatic cancer is resistant to several therapies, as well as the early, preclinical promise observed with immunotherapy.

Dr. Drilon on Immunotherapy in Lung Cancer

March 28th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with lung cancer.

Dr. Papadimitrakopoulou on Immunotherapy Combinations in Lung Cancer

March 28th 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses trials investigating combinations of immunotherapy regimens in lung cancer.

Dr. Smith Discusses CAR T Cells in Multiple Myeloma

March 28th 2017

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Gajewski on Targets Being Explored in Melanoma

March 28th 2017

Thomas F. Gajewski, MD, PhD, professor of medicine at The University of Chicago Medicine, discusses what targets are currently being explored in patients with melanoma.

Dr. O'Shaughnessy on Role of Chemotherapy in Future TNBC Treatment

March 28th 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, Texas Oncology, and chair of The US Oncology Network, and 2016 Giant of Cancer Care in Community Outreach, discusses the future role of chemotherapy in the treatment landscape of triple-negative breast cancer.

Dr. Beddoe on Ongoing Trials for Patients With Cervical Cancer

March 28th 2017

Ann Marie Beddoe, MD, assistant professor, Obstetrics, Gynecology and Reproductive Science, Gynecologic Oncology, Mount Sinai Hospital, discusses ongoing clinical trials for patients with cervical cancer.

Dr. Spigel on Pembrolizumab/Chemo Combo in First-Line NSCLC

March 27th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the results of cohort G from the KEYNOTE-021 trial, which explored pembrolizumab (Keytruda) combined with pemetrexed/carboplatin as a frontline treatment for patients with nonsquamous non–small cell lung cancer (NSCLC).

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

March 27th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Dr. Kumar on Studies Investigating Venetoclax in Multiple Myeloma

March 27th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myeloma.

Dr. Jackman on Overcoming Resistance to EGFR Inhibitors in Lung Cancer

March 27th 2017

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

Experts Raise Awareness for Colorectal Cancer

March 25th 2017

Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast Cancer

March 25th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.

Dr. Husain on the Future of Monitoring T790M in Lung Cancer

March 24th 2017

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).